Betta Pharmaceuticals
Betta Pharmaceuticals Co Ltd is a Chinese clinical-stage and commercial biopharmaceutical enterprise specializing in the discovery, development, and commercialization of innovative targeted oncology drugs and small molecule therapeutics for cancer treatment, prominently featuring icotinib (a pioneering epidermal growth factor receptor tyrosine kinase inhibitor). The company conducts advanced clinical research evaluating precision oncology medications designed to combat non-small cell lung cancer and other solid tumors. Its core business operations encompass biopharmaceutical research, clinical trial execution, precision oncology drug manufacturing, and commercial pharmaceutical distribution. Revenue is derived primarily from the wholesale and retail sale of targeted cancer therapies to hospitals and pharmacies. Betta Pharmaceuticals holds a leading market position in targeted oncology drug manufacturing in China. The company is headquartered in Hangzhou, Zhejiang Province, China, and its shares trade on the Shenzhen Stock Exchange.
2 of the funds FundTelligence covers report a position in Betta Pharmaceuticals.
- Legal name
- Betta Pharmaceuticals Co Ltd
- Sector
- Health Care
- Country
- China
- Funds holding it
- 2
Funds holding Betta Pharmaceuticals
- Handelsbanken Emerging Markets Index — Handelsbanken · 0.01 % (full portfolio disclosed, September 2026)
- Handelsbanken Global Index Criteria — Handelsbanken · 0.01 % (full portfolio disclosed, September 2026)